RESTEM is a leading clinical-stage biopharmaceutical company focused on the discovery and development of patient-specific, as well as off-the-shelf and ready-to-use, next-generation cell therapies that are designed to activate and enhance a patient’s own immune system. Our therapies are designed to enable the treatment of a broad range of disabling diseases that improve patient outcomes, as well as overall health and wellness for patients around the world.
Our mission at RESTEM is focused on developing transformative, next-generation cell therapies that offer the potential to revolutionize medicine and routine clinical care and we are dedicated to bringing these therapies to patients around the world as rapidly as possible.
RESTEM’s cell therapy platform technology is based on programs, our umbilical cord lining stem cell (ULSC) program, and our natural killer cell (NK) therapy program. We are also developing next-generation therapies based on these two foundational programs.